Literature DB >> 26782596

Associations between matrix metalloproteinase gene polymorphisms and the development of cerebral infarction.

J H Zhao1,2, Y M Xu1, H X Xing2, L L Su2, S B Tao2, X J Tian2, H Q Yan2, S B Ji2.   

Abstract

The aim of this study was to investigate the association between MMP3 rs3025058 and MMP9 rs3918242 polymorphisms and the development of ischemic stroke in a Chinese population. Between May 2013 and January 2015, 335 patients with ischemic stroke and 335 health control subjects were enrolled in this study. The MMP3 rs3025058 and MMP9 rs3918242 polymorphisms were analyzed using polymerase chain reaction coupled with restriction fragment length polymorphism. By multivariate logistic regression analysis, the CC genotype of MMP9 rs3918242 was shown to be associated with a significantly increased risk of ischemic stroke when compared with the TT genotype [OR (95%CI) = 5.47 (2.64-12.38)]. The TC+CC genotype of MMP9 rs3918242 was furthermore found to be associated with an elevated risk of ischemic stroke in higher BMI individuals [OR (95%CI) = 1.81 (1.03-3.22)]. The findings of this study suggest that the MMP9 rs3918242 polymorphism is associated with an elevated risk of ischemic stroke and that this gene polymorphism interacts with BMI in the risk of ischemic stroke.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26782596     DOI: 10.4238/2015.December.30.3

Source DB:  PubMed          Journal:  Genet Mol Res        ISSN: 1676-5680


  9 in total

1.  Genetic Variation of Inflammatory Genes to Ischemic Stroke Risk in a Chinese Han Population.

Authors:  Zhongqiu Zhang; Yanping Mei; Mengqiu Xiong; Fang Lu; Xianghong Zhao; Junrong Zhu; Bangshun He
Journal:  Pharmgenomics Pers Med       Date:  2021-08-13

2.  Matrix metalloproteinase-9 gene polymorphisms and their interaction with environment on subarachnoid hemorrhage risk.

Authors:  Tao Wang; Wanxing Fu; Shuang Song; Yanlong Han; Lihong Yao; Youkui Lu; Junshuai Zheng; Jing Wang
Journal:  Exp Biol Med (Maywood)       Date:  2018-05

3.  Combined effects of age and polymorphisms in Notch3 in the pathogenesis of cerebral infarction disease.

Authors:  Chun-Yu Zhu; Yue Wang; Qing-Xuan Zeng; Yu Qian; Huan Li; Zi-Xia Yang; Ya-Mei Yang; Qiong Zhang; Fei-Feng Li; Shu-Lin Liu
Journal:  Metab Brain Dis       Date:  2016-07-02       Impact factor: 3.584

Review 4.  Neurovascular Unit as a Source of Ischemic Stroke Biomarkers-Limitations of Experimental Studies and Perspectives for Clinical Application.

Authors:  Aleksandra Steliga; Przemysław Kowiański; Ewelina Czuba; Monika Waśkow; Janusz Moryś; Grażyna Lietzau
Journal:  Transl Stroke Res       Date:  2019-11-07       Impact factor: 6.800

5.  Matrix Metalloproteinase-9 Gene Polymorphism and Its Methylation in Stroke Patients.

Authors:  Omkar Kalidasrao Choudhari; Anita Rani; Geeta Kampani; Charanjeet Kaur; Ananya Sengupta
Journal:  Malays J Med Sci       Date:  2021-12-22

6.  Observation of the Effect of Nursing BPR on Thrombolytic Efficacy and Prognosis of Patients with Cerebral Infarction Based on CT Images.

Authors:  Shaomin Wang; Xiao Miao; Guanghui Zhang; Dandan Li; Li Xu
Journal:  Contrast Media Mol Imaging       Date:  2022-09-14       Impact factor: 3.009

7.  Association of the matrix metalloproteinase-3 polymorphisms rs679620 and rs3025058 with ischemic stroke risk: a meta-analysis.

Authors:  Qi-Wei Zhang
Journal:  Neuropsychiatr Dis Treat       Date:  2018-01-31       Impact factor: 2.570

8.  RBPJ polymorphisms associated with cerebral infarction diseases in Chinese Han population: A Clinical Trial/Experimental Study (CONSORT Compliant).

Authors:  Qiong Zhang; Jie Zhou; Hong Lei; Chun-Yu Zhu; Fei-Feng Li; Dong Zheng; Shu-Lin Liu
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817

9.  Meta-analysis of matrix metalloproteinase (MMP)-9 C1562T polymorphism and susceptibility to ischemic stroke in the Chinese population.

Authors:  Yan Jiang; HongYu Liu; Yukai Wang; Xinxiu Shi; Yankun Shao; ZhongXin Xu
Journal:  J Int Med Res       Date:  2020-06       Impact factor: 1.671

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.